Archives

Leads Biolabs’ PD-L1/4-1BB Bispecific Antibody Wins Pivotal Phase III Approval, Set to Reshape the Frontline Treatment Landscape for Advanced EP-NEC

B NANJING, China, May 18, 2026 /PRNewswire/ — Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that its… Login to continue reading Login…

Read MoreLeads Biolabs’ PD-L1/4-1BB Bispecific Antibody Wins Pivotal Phase III Approval, Set to Reshape the Frontline Treatment Landscape for Advanced EP-NEC

Rosen Law Firm Encourages PennyMac Financial Services, Inc. Investors to Inquire About Securities Class Action Investigation – PFSI

B NEW YORK, May 18, 2026 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf… Login to continue reading Login…

Read MoreRosen Law Firm Encourages PennyMac Financial Services, Inc. Investors to Inquire About Securities Class Action Investigation – PFSI

ROSEN, A LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ALDX

B NEW YORK, May 18, 2026 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc.… Login to continue reading Login…

Read MoreROSEN, A LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ALDX

Accro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases

B Financing led by OrbiMed with participation from TCGX, LAV, Cenova Capital and existing investors SCGC and Oriza Proceeds will advance multi-asset pipeline including AC-101,… Login to continue reading Login…

Read MoreAccro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases